Rice Hall James & Associates LLC Sells 24,454 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Rice Hall James & Associates LLC lowered its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 10.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 210,622 shares of the medical instruments supplier's stock after selling 24,454 shares during the quarter. LeMaitre Vascular comprises approximately 1.0% of Rice Hall James & Associates LLC's holdings, making the stock its 27th largest holding. Rice Hall James & Associates LLC owned 0.93% of LeMaitre Vascular worth $17,671,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in LMAT. CBIZ Investment Advisory Services LLC raised its stake in LeMaitre Vascular by 38.5% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after buying an additional 117 shares during the period. Summit Investment Advisors Inc. raised its stake in LeMaitre Vascular by 8.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 2,122 shares of the medical instruments supplier's stock worth $196,000 after buying an additional 160 shares during the period. HighTower Advisors LLC raised its stake in LeMaitre Vascular by 3.9% during the 4th quarter. HighTower Advisors LLC now owns 5,683 shares of the medical instruments supplier's stock worth $524,000 after buying an additional 212 shares during the period. Bank of Montreal Can raised its stake in LeMaitre Vascular by 8.3% during the 4th quarter. Bank of Montreal Can now owns 2,926 shares of the medical instruments supplier's stock worth $270,000 after buying an additional 223 shares during the period. Finally, Fifth Third Bancorp raised its stake in LeMaitre Vascular by 2.3% during the 1st quarter. Fifth Third Bancorp now owns 10,903 shares of the medical instruments supplier's stock worth $915,000 after buying an additional 246 shares during the period. Institutional investors and hedge funds own 84.64% of the company's stock.

LeMaitre Vascular Stock Down 1.3%

LMAT stock traded down $1.12 during trading hours on Tuesday, reaching $82.97. 27,982 shares of the stock were exchanged, compared to its average volume of 169,277. The firm's 50-day moving average is $82.72 and its 200-day moving average is $88.07. The company has a market cap of $1.87 billion, a price-to-earnings ratio of 41.91, a PEG ratio of 2.21 and a beta of 0.82. The company has a debt-to-equity ratio of 0.48, a current ratio of 16.49 and a quick ratio of 13.83. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The firm had revenue of $59.87 million for the quarter, compared to the consensus estimate of $57.61 million. LeMaitre Vascular had a return on equity of 13.53% and a net margin of 19.96%. LeMaitre Vascular's revenue for the quarter was up 12.0% on a year-over-year basis. During the same quarter last year, the company posted $0.44 EPS. On average, equities research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date of this dividend was Thursday, May 15th. LeMaitre Vascular's dividend payout ratio (DPR) is presently 40.40%.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 76,868 shares of the stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $85.79, for a total transaction of $6,594,505.72. Following the completion of the transaction, the chief executive officer owned 1,796,783 shares in the company, valued at approximately $154,146,013.57. This represents a 4.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders sold 100,000 shares of company stock worth $8,556,857. 9.50% of the stock is currently owned by corporate insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.